|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1972
|
|
gptkbp:ATCCode
|
gptkb:N05AH02
|
|
gptkbp:blackBoxWarning
|
gptkb:orthostatic_hypotension
seizures
myocarditis
agranulocytosis
|
|
gptkbp:brand
|
gptkb:FazaClo
gptkb:Versacloz
gptkb:Clozaril
|
|
gptkbp:CASNumber
|
gptkb:5786-21-0
|
|
gptkbp:chemicalFormula
|
C18H19ClN4
|
|
gptkbp:color
|
yellow
|
|
gptkbp:contraindication
|
history of agranulocytosis
uncontrolled epilepsy
severe cardiac disease
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:clozapine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clozaril
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
regular blood tests
|
|
gptkbp:pregnancyCategory
|
C (US)
B (Australia)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskFactor
|
gptkb:metabolic_syndrome
neutropenia
sudden cardiac death
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
weight gain
seizures
myocarditis
agranulocytosis
hypersalivation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target
|
gptkb:muscarinic_acetylcholine_receptor
gptkb:serotonin_5-HT2A_receptor
antihistamine
adrenergic alpha-1 receptor
dopamine D2 receptor
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Sandoz_Laboratories
gptkb:clozapine
|
|
gptkbp:bfsLayer
|
6
|